C5a and Its Role in Age-related Macular Degeneration
Author Information
Author(s): Liu Baoying, Wei Lai, Meyerle Catherine, Tuo Jingsheng, Sen H Nida, Li Zhiyu, Chakrabarty Sagarika, Agron Elvira, Chan Chi-Chao, Klein Michael L, Chew Emily, Ferris Frederick, Nussenblatt Robert B
Primary Institution: National Eye Institute, National Institutes of Health
Hypothesis
Does complement component C5a impact human T cells and contribute to age-related macular degeneration (AMD)?
Conclusion
C5a may contribute to elevated levels of IL-22 and IL-17 in AMD patients, suggesting a potential target for treatment.
Supporting Evidence
- C5a was found to promote IL-22 and IL-17 expression in CD4+ T cells.
- Elevated levels of IL-22 and IL-17 were observed in AMD patients compared to controls.
- Monocytes were necessary for C5a to induce IL-22 and IL-17 expression from T cells.
Takeaway
C5a helps certain immune cells in the body produce substances that can cause inflammation, which might be linked to a common eye disease in older people.
Methodology
Human peripheral blood mononuclear cells were isolated from AMD patients and healthy controls, and cytokine levels were measured using ELISA and flow cytometry.
Potential Biases
Potential selection bias due to the specific demographic of participants (Caucasian AMD patients).
Limitations
The study does not establish a direct causal relationship between C5a levels and Th17 cytokine production in AMD patients.
Participant Demographics
Participants included 40 AMD patients and 45 healthy controls, all Caucasian, with a range of ages from 57 to 97.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website